Cat. #151244
Anti-Cdk2 [AN4.3]
Cat. #: 151244
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Cyclin-dependent kinase 2 (cdk2)
Class: Monoclonal
Application: ELISA ; FACS ; IP ; WB
Reactivity: Human ; Mouse ; Xenopus laevis
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Julian Gannon
Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Cdk2 [AN4.3]
- Alternate name: Cyclin-Dependent Kinase 2; Cell Division Protein Kinase 2; P33 Protein Kinase; CDKN2; CDC2-Related Protein Kinase; P33(CDK2)
- Research fields: Cancer;Cell biology;Genetics
- Clone: AN4.3
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human ; Mouse ; Xenopus laevis
- Host: Mouse
- Application: ELISA ; FACS ; IP ; WB
- Description: Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase.
- Immunogen: Human recombinant Cdk2
- Isotype: IgG2a
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: Cyclin-dependent kinase 2 (cdk2)
- Target background: Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase.
Applications
- Application: ELISA ; FACS ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Syafrizayanti et al. 2017. Sci Rep. 7:39756. PMID: 28045055.
- Chang et al. 2016. J Formos Med Assoc. :. PMID: 27773559.
- Chu et al. 2016. Journal of Fn Foods. 23:614-627
- Xu et al. 2010. Biol Pharm Bull. 33(5):743-51. PMID: 20460749.
- Ottewell et al. 2009. Mol Cancer Ther. 8(10):2821-32. PMID: 19789217
